Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

C Fruchart

Showing results (501-510 of 562) with videos related to

Pageof 57
Sort By:
Journal of Cardiovascular Pharmacology|October 22, 1998
A high concentration of melatonin inhibits in vitro LDL peroxidation but not oxidized LDL toxicity toward cultured endothelial cellsE Walters-Laporte, C Furman, S Fouquet, et al.
Clinica Chimica Acta; International Journal of Clinical Chemistry|March 4, 1999
Abnormal capacity to induce cholesterol efflux and a new LpA-I pre-beta particle in type 2 diabetic patientsF D Brites, E Cavallero, C de Geitere, et al.
Circulation|May 11, 1999
Beneficial effects of fibrates on apolipoprotein A-I metabolism occur independently of any peroxisome proliferative responseN Hennuyer, P Poulain, L Madsen, et al.
The Journal of Clinical Investigation|June 1, 1996
Opposite regulation of human versus mouse apolipoprotein A-I by fibrates in human apolipoprotein A-I transgenic miceL Berthou, N Duverger, F Emmanuel, et al.
Journal of Lipid Research|December 20, 1999
Modulation of rat liver apolipoprotein gene expression and serum lipid levels by tetradecylthioacetic acid (TTA) via PPARalpha activationE Raspé, L Madsen, A M Lefebvre, et al.
Biochemical Society Transactions|November 1, 2006
PPAR: a new pharmacological target for neuroprotection in stroke and neurodegenerative diseasesR Bordet, T Ouk, O Petrault, et al.
European Journal of Clinical Pharmacology|January 1, 1989
Effect of simvastatin on plasma lipids, apolipoproteins and lipoprotein particles in patients with primary hypercholesterolaemiaJ M Bard, G Luc, P Douste-Blazy, et al.
Biochemical and Biophysical Research Communications|February 12, 1998
Endothelial derived vasorelaxation is impaired in human APO A-I transgenic rabbitsG Lebuffe, A Boullier, A Tailleux, et al.
Nutrition, Metabolism, and Cardiovascular Diseases : NMCD|February 24, 2001
Prevention of coronary heart disease in post-menopausal womenP Cullen, A von Eckardstein, E Barrett-Connor, et al.
Science (New York, N.Y.)|October 6, 2001
An apolipoprotein influencing triglycerides in humans and mice revealed by comparative sequencingL A Pennacchio, M Olivier, J A Hubacek, et al.
Pageof 57

Showing results (501-510 of 562) with videos related to

Sort By:
Pageof 57
Journal of Cardiovascular Pharmacology|October 22, 1998
A high concentration of melatonin inhibits in vitro LDL peroxidation but not oxidized LDL toxicity toward cultured endothelial cellsE Walters-Laporte, C Furman, S Fouquet, et al.
Clinica Chimica Acta; International Journal of Clinical Chemistry|March 4, 1999
Abnormal capacity to induce cholesterol efflux and a new LpA-I pre-beta particle in type 2 diabetic patientsF D Brites, E Cavallero, C de Geitere, et al.
Circulation|May 11, 1999
Beneficial effects of fibrates on apolipoprotein A-I metabolism occur independently of any peroxisome proliferative responseN Hennuyer, P Poulain, L Madsen, et al.
The Journal of Clinical Investigation|June 1, 1996
Opposite regulation of human versus mouse apolipoprotein A-I by fibrates in human apolipoprotein A-I transgenic miceL Berthou, N Duverger, F Emmanuel, et al.
Journal of Lipid Research|December 20, 1999
Modulation of rat liver apolipoprotein gene expression and serum lipid levels by tetradecylthioacetic acid (TTA) via PPARalpha activationE Raspé, L Madsen, A M Lefebvre, et al.
Biochemical Society Transactions|November 1, 2006
PPAR: a new pharmacological target for neuroprotection in stroke and neurodegenerative diseasesR Bordet, T Ouk, O Petrault, et al.
European Journal of Clinical Pharmacology|January 1, 1989
Effect of simvastatin on plasma lipids, apolipoproteins and lipoprotein particles in patients with primary hypercholesterolaemiaJ M Bard, G Luc, P Douste-Blazy, et al.
Biochemical and Biophysical Research Communications|February 12, 1998
Endothelial derived vasorelaxation is impaired in human APO A-I transgenic rabbitsG Lebuffe, A Boullier, A Tailleux, et al.
Nutrition, Metabolism, and Cardiovascular Diseases : NMCD|February 24, 2001
Prevention of coronary heart disease in post-menopausal womenP Cullen, A von Eckardstein, E Barrett-Connor, et al.
Science (New York, N.Y.)|October 6, 2001
An apolipoprotein influencing triglycerides in humans and mice revealed by comparative sequencingL A Pennacchio, M Olivier, J A Hubacek, et al.
Pageof 57